Ribometrix
Biotechnology company leveraging proprietary RNA structure determination, state-of-the-art RNA tools and technologies, and AI/ML capabilities to directly target and modulate RNA biology with small molecules.
Notes
Ribometrix is a biotechnology company pioneering the discovery of small molecule drugs that directly target RNA. Founded in 2016 and headquartered in Durham, North Carolina, the company leverages proprietary RNA structure determination technologies combined with AI/ML capabilities to identify and develop drugs that modulate RNA biology.
The company's platform enables the identification of druggable RNA structures and the discovery of small molecules that can bind to and modulate these targets. This approach opens up a vast new landscape of therapeutic targets beyond traditional proteins.
Ribometrix's technology is based on foundational work from the laboratory of Kevin Weeks at the University of North Carolina.
Team
- Michael Bhogal - Chief Executive Officer
- Kevin Weeks, Ph.D. - Co-founder & Chief Scientific Officer
- Professor at University of North Carolina
- LinkedIn: linkedin.com/in/kevin-weeks
Additional Research Findings
- Founded in 2016
- RNA structure-based drug discovery
- AI/ML integration for target identification
- Small molecule therapeutics targeting RNA
- Spun out of University of North Carolina research
- Durham, North Carolina headquarters
- Focus on previously undruggable RNA targets
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |